Literature DB >> 21055435

The acute and chronic effects of combined antipsychotic-mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes.

Carmine Tomasetti1, Carmela Dell'Aversano, Felice Iasevoli, Federica Marmo, Andrea de Bartolomeis.   

Abstract

The detection of changes in postsynaptic gene expression after the administration of mood stabilizers, alone or in combination with antipsychotics, and antidepressants in animal models of drug treatment, may represent a valuable strategy to explore the molecular targets of the mainstay treatments for bipolar disorder. In this study we investigated, in both acute and chronic paradigms, the expression of specific postsynaptic density genes (Homer1a, Homer1b/c, and PSD95) and genes putatively implicated in mood stabilizers mechanism of action (GSK3b, ERK) after administration of first (haloperidol) or second generation antipsychotics (quetiapine 30 mg/kg), alone or in combination with valproate. Moreover, we compared the effects of an antidepressant agent widely used in bipolar depression (citalopram) with a low dose of quetiapine (15 mg/kg), which has been demonstrated to display antidepressant action in bipolar depression. In striatal regions, Homer1a expression was strongly induced by haloperidol compared to all the other treatments. Haloperidol plus valproate also markedly induced Homer1a, but to a significant lesser extent than haloperidol alone. Also in the chronic paradigm haloperidol, but not haloperidol plus valproate, induced Homer1a expression in all the subregions of the caudate-putamen and in the nucleus accumbens core. The high dose of quetiapine significantly induced Homer1a in anterior cingulated, premotor and motor subregions of the cortex, and the extent of induction was significantly higher as compared to the lower dose. Oppositely, Homer1a expression was decreased in the cortex by citalopram acute administration. ERK gene was upregulated in cortex and striatum by the acute treatment with valproate and with the combination of haloperidol or quetiapine plus valproate, whereas no significant differences were noticed in GSK3b expression among treatments. PSD95 showed a significant upregulation by acute citalopram and by haloperidol plus valproate in both cortical and subcortical regions. Haloperidol and quetiapine 30 mg/kg, oppositely, significantly reduced the expression of the gene in the cortex. In conclusion, these results suggest that the combined treatment with a typical or an atypical antipsychotic plus valproate may induce differential modulation of postsynaptic genes expression when compared to the effects of these drugs individually administered.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21055435     DOI: 10.1016/j.pnpbp.2010.10.025

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  16 in total

Review 1.  Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches.

Authors:  Andrea de Bartolomeis; Gianmarco Latte; Carmine Tomasetti; Felice Iasevoli
Journal:  Mol Neurobiol       Date:  2013-09-03       Impact factor: 5.590

Review 2.  Scaffolding proteins of the post-synaptic density contribute to synaptic plasticity by regulating receptor localization and distribution: relevance for neuropsychiatric diseases.

Authors:  Felice Iasevoli; Carmine Tomasetti; Andrea de Bartolomeis
Journal:  Neurochem Res       Date:  2012-09-19       Impact factor: 3.996

3.  Chronic treatment with lithium or valproate modulates the expression of Homer1b/c and its related genes Shank and Inositol 1,4,5-trisphosphate receptor.

Authors:  Andrea de Bartolomeis; Carmine Tomasetti; Maria Cicale; Pei-Xiong Yuan; Husseini K Manji
Journal:  Eur Neuropsychopharmacol       Date:  2012-01-14       Impact factor: 4.600

4.  Radiosynthesis and in Vivo Evaluation of [11C]A1070722, a High Affinity GSK-3 PET Tracer in Primate Brain.

Authors:  Jaya Prabhakaran; Francesca Zanderigo; Kiran Kumar Solingapuram Sai; Harry Rubin-Falcone; Matthew J Jorgensen; Jay R Kaplan; Akiva Mintz; J John Mann; J S Dileep Kumar
Journal:  ACS Chem Neurosci       Date:  2017-05-17       Impact factor: 4.418

5.  Homer1a protein expression in schizophrenia, bipolar disorder, and major depression.

Authors:  Stefan L Leber; Ida C Llenos; Christine L Miller; Jeannette R Dulay; Johannes Haybaeck; Serge Weis
Journal:  J Neural Transm (Vienna)       Date:  2017-08-16       Impact factor: 3.575

Review 6.  Calcium-dependent networks in dopamine-glutamate interaction: the role of postsynaptic scaffolding proteins.

Authors:  Andrea de Bartolomeis; Carmine Tomasetti
Journal:  Mol Neurobiol       Date:  2012-07-05       Impact factor: 5.590

7.  Protein expression of targets of the FMRP regulon is altered in brains of subjects with schizophrenia and mood disorders.

Authors:  Timothy D Folsom; Paul D Thuras; S Hossein Fatemi
Journal:  Schizophr Res       Date:  2015-05-05       Impact factor: 4.939

8.  Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid.

Authors:  F Calabrese; A Luoni; G Guidotti; G Racagni; F Fumagalli; M A Riva
Journal:  Psychopharmacology (Berl)       Date:  2012-10-24       Impact factor: 4.530

Review 9.  Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins.

Authors:  A de Bartolomeis; E F Buonaguro; F Iasevoli
Journal:  Psychopharmacology (Berl)       Date:  2012-11-21       Impact factor: 4.530

10.  Quetiapine and aripiprazole signal differently to ERK, p90RSK and c-Fos in mouse frontal cortex and striatum: role of the EGF receptor.

Authors:  Avril Pereira; Betty Zhang; Peter Malcolm; Anthony Sugiharto-Winarno; Suresh Sundram
Journal:  BMC Neurosci       Date:  2014-02-20       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.